An Asia-based global chemical company that serves the chemical, petrochemical and bioscience markets among other markets, has recently started a corporate venture initiative with a $300M budget to make strategic investments into both pre and post-commercial companies. The group is flexible in terms of structuring investments and may employ equity investments, M&A and licensing agreements. The group targets investment sizes from $100k – $5M for early stage companies and $10M – $50M for commercial-stage companies.
In terms of the healthcare and life science sectors, the group is most interested in companies working in diagnostics and research tools. The group is particularly interested in clinical diagnostics including IVDs and next generation platforms (NGS, liquid biopsy, LC-MS, point-of-care testing, digital PCR), separation media and connected devices and wearable medical sensors. The group is also interested in advanced materials including materials for secondary batteries, thin-film for electronic devices, separation (inorganic/organic/polymers) and composites. The group is agnostic to indication area, but has a particular interest in cancer, metabolic (including diabetes) and kidney disorders as well as reproductive health.
The group has no strict company or management team requirements and invest in both early and later stage opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment